Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Withdrawn 1Suspended 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Primary Malignant Peripheral Nerve Sheath Tumors 1

Interventions

Magnetic Resonance Spectroscopy 17Cyclophosphamide 16fludarabine 12Specimen Handling 12Fluorodeoxyglucose F18 7pembrolizumab 6X-Rays 6Nivolumab 6Temozolomide 5Radiotherapy 5Immunotherapy, Adoptive 5lenvatinib 4Paclitaxel 4Leukapheresis 4Immune Checkpoint Inhibitors 4Etoposide 4Cisplatin 4Carboplatin 4ruxolitinib 3fluciclovine F-18 3Tirzepatide 3Surgical Procedures, Operative 3Doxorubicin 3Dasatinib 3Cholecalciferol 3Biopsy 368Ga-FAPI 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2palbociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recruiting × Vorinostat × Clear all
NCT06693284 2026-02-03

A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]

University of Minnesota

Phase EARLY_PHASE1 Recruiting
8 enrolled

Primary Malignant Peripheral Nerve Sheath Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡